These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 7059436)

  • 21. Isoniazid acetylator status of Black South African tuberculosis patients.
    Bach PH; Higgins-Opitz SB; Bima B; Leary WP
    S Afr Med J; 1976 Jul; 50(29):1132-4. PubMed ID: 959925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between serum isonicotinic acid hydrazide (INH) levels and urinary sulfadimidine (sulfamethazine) acetylation as predictors of INH acetylator status.
    Seth V; Seth SD; Beotra A; Singh U
    Dev Pharmacol Ther; 1988; 11(1):32-6. PubMed ID: 3383719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators.
    Samigun ; Mulyono ; Santoso B
    Br J Clin Pharmacol; 1990 May; 29(5):570-3. PubMed ID: 2350534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A simple method for determining acetylator phenotype using isoniazid.
    Hutchings A; Routledge PA
    Br J Clin Pharmacol; 1986 Sep; 22(3):343-5. PubMed ID: 3768246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype.
    Gibson TP; Matusik J; Matusik E; Nelson HA; Wilkinson J; Briggs WA
    Clin Pharmacol Ther; 1975 Apr; 17(4):395-9. PubMed ID: 1122681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normal distribution of acetylation phenotypes in systemic lupus erythematosus.
    Vansant J; Woosley RL; John JT; Sergent JS
    Arthritis Rheum; 1978 Mar; 21(2):192-5. PubMed ID: 637885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical consequences of polymorphic acetylation of basic drugs.
    Drayer DE; Reidenberg MM
    Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of isoniazid half-life from salivary samples.
    Suryawati S; Santoso B
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):18-22. PubMed ID: 3957485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
    Ylitalo P; Auterinen L; Marttinen A; Koivula T
    Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphic acetylator phenotype and systemic lupus erythematosus.
    Johansson E; Mustakallio KK; Mattila MJ
    Acta Med Scand; 1981; 210(3):193-6. PubMed ID: 6974957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.
    Strandberg I; Boman G; Hassler L; Sjöqvist F
    Acta Med Scand; 1976; 200(5):367-71. PubMed ID: 983808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of human lymphocyte N-acetyltransferase and its relationship to the isoniazid acetylator polymorphism.
    McQueen CA; Weber WW
    Biochem Genet; 1980 Oct; 18(9-10):889-904. PubMed ID: 7225085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetylator phenotype in systemic lupus erythematosus.
    Foad B; Litwin A; Zimmer H; Hess EV
    Arthritis Rheum; 1977 Apr; 20(3):815-8. PubMed ID: 301027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe.
    Aït Moussa L; Khassouani CE; Hüe B; Jana M; Bégaud B; Soulaymani R
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):548-53. PubMed ID: 12503812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bioavailability of isoniazid in healthy volunteers--fast and slow INH acetylators].
    Augustynowicz-Kopeć E; Zwolska Z; Niemirowska-Mikulska H
    Pneumonol Alergol Pol; 2002; 70(3-4):167-79. PubMed ID: 12271964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus.
    Baer AN; Woosley RL; Pincus T
    Arthritis Rheum; 1986 Apr; 29(4):508-14. PubMed ID: 3707628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of association between slow acetylator status and spontaneous lupus erythematosus.
    Kumana CR; Chan MM; Wong KL; Wong RW; Kou M; Lauder IJ
    Clin Pharmacol Ther; 1990 Aug; 48(2):208-13. PubMed ID: 2379389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of isoniazid: influence of age.
    Kergueris MF; Bourin M; Larousse C
    Eur J Clin Pharmacol; 1986; 30(3):335-40. PubMed ID: 3732371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
    Sonnhag C; Karlsson E; Hed J
    Acta Med Scand; 1979; 206(4):245-51. PubMed ID: 92167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.